1 Vasospasm of arterial conduits used for coronary artery surgery is an important cause of graft failure and is likely to result partly from raised levels of vasoconstrictor substances such as thromboxane A 2 and endothelin-1. Our aim was to ®nd pharmacological agents that could prevent agonist-induced vasospasm. 2 Isometric tension was recorded from discarded segments of human left internal mammary artery (LIMA). Submaximal contraction evoked by the thromboxane A 2 mimetic U46619 (10 nM) was not inhibited by a blocker of store-and receptor-operated Ca 2+ channels (30 mM SKF96365) in the presence of diltiazem. Furthermore, contractions to 41 nM U46619 were preserved when extracellular Ca 2+ was reduced from 2.5 mM to 60 nM. Thus, sustained U46619-evoked contraction occurred without Ca 2+ in¯ux. 3 We hypothesized that contraction might occur via Rho-kinase-mediated Ca 2+ -sensitization of myo®laments. Inhibitors of Rho-kinase (Y27632 and HA1077) were profound relaxants. If contraction was pre-evoked by 10 nM U46619, Y27632 and HA1077 caused full relaxation with EC 50 s of 1.67+0.22 mM and 3.58+0.35 mM respectively. Y27632 was also eective if applied before U46619, but was less potent. 4 Y27632 abolished contraction evoked by endothelin-1 and signi®cantly reduced resting tone in the absence of a vasoconstrictor. 5 Rho-kinase-mediated Ca 2+ -sensitization appears to be a major mechanism of vasoconstriction in human LIMA. Rho-kinase inhibitors may have an important role in preventing vasospasm in arterial grafts used for coronary artery surgery.
Introduction
Vasospasm of arterial conduits is an important cause of graft failure and morbidity in patients undergoing coronary artery surgery (He et al., 1989; Sarabu et al., 1987; Cable et al., 1998; He 1999; Rosenfeldt et al., 1999) . With the current trend towards total arterial revascularization, it has become essential to identify both the causes of vasospasm and potential therapeutic targets.
The aetiology of graft vasospasm is likely to be multifactorial, including trauma at the time of surgery, endothelial disruption and the presence of vasoactive substances. Endothelin-1 (ET-1) and thromboxane A 2 (TXA 2 ) are two of the most potent endogenous vasoconstrictors , circulating levels of which have been shown to rise at the time of surgery (Watkins et al., 1982; Faymonville et al., 1986) . ET-1 is released by the endothelium, whereas the prostanoid TXA 2 is released from platelets. Other vasoconstrictor substances include noradrenaline, 5-hydroxytryptamine, acetylcholine, histamine and angiotensin II (He 1999) , whilst exogenous vasoconstrictors such as phenylephrine, a drug used to support the circulation perioperatively, may also be implicated.
Clinically, a number of drugs have been used to prevent arterial graft spasm, including diltiazem, papaverine and nitrates. Other drugs have been studied in vitro as potential antispasmogens and include L-type Ca 2+ channel blockers (e.g. diltiazem, verapamil, nifedipine) (He et al., 1989; Cable et al., 1998; He & Yang, 2000a; Sadaba et al., 2000) , nitrates (He et al., 1989; Cable et al., 1998) , phosphodiesterase inhibitors (e.g. papaverine, milrinone, enoximone, amrinone) (He et al., 1989; SalmenperaÈ & Levy, 1996; He & Yang, 2000b) , TXA 2 antagonists and nicorandil (Sadaba et al., 2000) . The commonly administered Ca 2+ antagonists may be completely ineective against contractions evoked by some endogenous vasoconstrictors (Sadaba et al., 2000) . Many other drugs have only modest relaxant eects or must be The ®rst two authors contributed equally to this paper.
used at high concentrations in order to inhibit vasospasm eectively.
Until recently there has been poor understanding of the intracellular events leading to contraction in human vascular smooth muscle cells. Agents such as diltiazem, nifedipine and verapamil prevent entry of Ca 2+ into the cell via voltage-operated Ca 2+ channels (VOCCs) (Morel & Godfraind, 1993) . Ca 2+ may also enter the cell via receptor-operated Ca 2+ channels (ROCCs) (Barritt, 1999) . In addition, agonist occupancy of cell-surface receptors linked to phospholipase C generates inositol triphosphate, triggering the release of Ca 2+ from the sarcoplasmic reticulum. Depletion of Ca 2+ from intracellular stores is itself a trigger for the opening of store-operated Ca 2+ entry channels (SOCCs) (Lewis, 1999) . All these events lead to a rise in intracellular Ca 2+ and increased activity of Ca 2+ -calmodulin-modulated myosin light chain kinase (MLCK) (Somlyo & Somlyo, 2000) , an enzyme that phosphorylates myosin light chain (MLC) and consequently promotes contraction.
Smooth muscle contraction does not necessarily require an increase in intracellular Ca
2+
. A decade ago it was shown that U46619, a stable TXA 2 mimetic, caused little or no rise in intracellular Ca 2+ in rabbit pulmonary artery despite evoking contractions (Himpens et al., 1990) . Sensitization of the contractile apparatus to Ca 2+ is now an established phenomenon (Somlyo & Somlyo, 2000) . Although protein kinase C and arachidonic acid may play a role in Ca 2+ -sensitization, the main mechanism appears to involve the monomeric G-protein RhoA (Somlyo & Somlyo, 2000; Uehata et al., 1997; Fu et al., 1998) . Activation of cellsurface receptors activates RhoA which binds GTP and translocates to the cell membrane. Its eector is a serinethreonine kinase known as Rho-kinase (Fu et al., 1998) . Rho-kinase phosphorylates myosin phosphatase (MLCP), which inhibits the activity of MLCP (Kimura et al., 1996) . Inactive MLCP cannot dephosphorylate MLC, and so Rhokinase activity removes inhibition of MLC phosphorylation, allowing MLCK, and contraction, to dominate. Thus, regulation of MLC phosphorylation depends on Ca 2+ -dependent (via MLCK) and Ca
-independent (via Rhokinase) mechanisms.
Our aim was to determine the dominant mechanisms responsible for agonist-induced contraction in human left internal mammary artery (LIMA) and thus reveal an important target for new anti-vasospastic drugs. We have previously shown that blockers of L-type Ca 2+ channels have only weak eects (Sadaba et al., 2000) and so we focussed on other potential mechanisms including receptor-and storeoperated Ca 2+ entry and sensitization of the contractile apparatus to Ca 2+ .
Methods
Ethical approval was obtained from the Research Ethics Committee, Leeds Teaching Hospitals NHS Trust, Leeds, U.K. Samples were obtained anonymously from discarded segments of distal left internal mammary arteries from patients undergoing coronary artery bypass surgery. These samples were transported to the laboratory in Hanks solution at 48C. Loose connective tissue was removed and 3 mm rings prepared to be used either on the day of surgery or the following day. They were stored in Hanks solution at 48C or incubated overnight in Dulbecco's Modi®ed Eagle Medium supplemented with 100 mg ml 71 penicillin G and 100 mg ml 71 streptomycin in a 5% CO 2 incubator at 378C. Hanks solution contained (in mM) NaCl 137, KCl 5.4, CaCl 2 0.01, NaH 2 PO 4 0.34, K 2 HPO 4 0.44, glucose 8, and HEPES 5 (pH 7.40).
The rings were mounted on two stainless steel hooks, one of which was ®xed and the other connected to an isometric tension transducer in a glass organ bath containing 15 ml of Krebs solution bubbled with 95% O 2 /5% CO 2 at 378C. Krebs solution contained (in mM) NaCl 118.3, KCl 4.6, MgSO 4 1.2, NaHCO 3 25, KH 2 PO 4 1.2, CaCl 2 2.5, and glucose 11. Low Ca 2+ solution diered in that it contained 5 mM EGTA (calculated free Ca 2+ =60 nM; this and all other free Ca 2+ values were calculated with Eqcal software) and was titrated to pH 7.40 with NaOH.
Arterial rings were routinely stretched to a resting tension of 1 g (Sadaba et al., 2000) and equilibrated for 90 min before being tested for three reproducible responses to phenylephrine.
All vessels were tested for the presence of functional endothelium by eliciting relaxation with carbachol (1 mM) in the presence of phenylephrine. Vessels exhibiting less than 10% relaxation were classed as intrinsically lacking functional endothelium. In experiments involving preincubation with Y27632 or GF 109203X, the arterial segments were contracted with Krebs solution containing 80 mM K + to allow comparison between vessels. Thereafter, all experiments occurred in the presence of 10 mM diltiazem to abolish Ca 2+ entry through voltage-gated Ca 2+ channels.
All statistical comparisons were made using either paired or independent two-tailed Student's t-test and dierences were taken to be statistically signi®cant at P50.05. Results are expressed as mean+s.e.mean, and the value n indicates the number of arterial segments. Data analysis and the mathematical ®tting of functions to data using a least-squares method were performed by the program Origin (version 4.1; MicroCal Inc, Northampton, MA, U.S.A.). Concentrationeect data were ®tted to the Hill equation:
where s is the slope and A is the maximum value of y. Normalized tension was calculated as the tension in grams divided by the wet weight of the arterial ring in grams. Diltiazem, carbachol, EGTA, U46619 and HEPES were from Sigma (Poole, Dorset, U.K.). SKF96365, HA1077 (fasudil) and endothelin-1 were from Calbiochem (Beeston, Nottingham, U.K.). GF 109203X was from Research Biochemicals International (Natick, MA, U.S.A.). Y27632 was a gift from the Wel®de Corporation (Saitama, Japan). General salts were from BDH (Merck Ltd.). Dulbecco's Modi®ed Eagle Medium was from Gibco BRL (Paisley, Scotland).
Stock solutions of diltiazem, Y27632, HA1077 and SKF96365 were prepared in water, while GF 109203X was prepared in dimethylsulphoxide (DMSO), U46619 in ethanol and endothelin-1 in 5% acetic acid. The ®nal concentration of DMSO, ethanol or acetic acid in the recording bath was always 40.01%.
Results

Contraction without Ca 2+ entry
Ca 2+ entry pathways other than voltage-operated Ca 2+ entry could be important for U46619-evoked contraction and thus we investigated the eect of SKF96365, a blocker of SOCCs and ROCCs in rat aorta smooth muscle cells (Merritt et al., 1990; Zhang et al., 1999) . Concentration-response curves were created for U46619 alone and then (after a washout) for U46619 following a 30-min preincubation with 30 mM SKF96365. There was no signi®cant change in the EC 50 or maximum eect of U46619 in time-matched control experiments (not shown) or in the presence of SKF96365 ( Figure  1A ). Although these data indicate that Ca 2+ entry pathways are not important for U46619-evoked contraction, they do not exclude a role for diltiazem-and SKF96365-resistant Ca 2+ -entry. To look more generally at Ca 2+ -entry we investigated the eect of lowering the external Ca 2+ concentration from 2.5 mM to 60 nM, a value at or just below that expected in the cytoplasm. Importantly, contractions to U46619 were still observed ( Figure 1B ) and contractions to 41 nM U46619 were unaected ( Figure  1C ). The maximum contraction to U46619 was reduced by about half (P=0.038) and the EC 50 decreased from 7.86+0.82 nM to 4.89+0.90 nM (P=0.021).
Thus, at least at low concentrations of U46619, Ca 2+ in¯ux is not a prerequisite for contraction, and pharmacologically identi®ed Ca 2+ channels do not appear to play an important role even when U46619 concentrations are high. However, the possibility exists that contractions to high concentrations of U46619 may occur partly via Ca 2+ release from the sarcoplasmic reticulum, and that these stores were depleted in 60 nM Ca 2+ solution.
Effects of Rho-kinase inhibitors
The Rho-kinase inhibitor HA1077 (Asano et al., 1989) completely reversed submaximal contraction evoked by 10 nM U46619 with an EC 50 of 3.58+0.35 mM (Figure 2 ). Y27632, a more potent and selective inhibitor of Rho-kinase (Uehata et al., 1997; Ishizaki et al., 2000) also completely reversed the contraction to 10 nM U46619 in endotheliumintact vessels with an EC 50 of 1.67+0.22 mM ( Figure 3A,B) . Y27632 was equally eective in vessels lacking a functional endothelium (n=3, data not shown). It was apparent that Y27632 caused relaxation to below pre-U46619 levels. Therefore, Y27632 (1 and 10 mM) was tested under basal conditions without precontraction with U46619 and was seen to cause a signi®cant relaxation ( Figure 3C ). The absolute amplitude of the Y27632-induced relaxation was substantially smaller than that in the presence of U46619 ( Figure 3A ,C), and thus Y27632 did relax U46619-evoked as well as basal tension. Unlike the Rho-kinase inhibitors, the protein kinase C inhibitor GF 109203X (1 mM) had no signi®cant eect on baseline tension ( Figure 3C ) or U46619-evoked contraction (n=4, data not shown).
Because it has been reported that Y27632 is less eective if applied prior to the vasoconstrictor agonist (Fu et al., 1998; Iizuka et al., 1999) vessels were preincubated with either Y27632 or vehicle for 30 min before a concentration-response curve was constructed to U46619 ( Figure 4A ). Y27632 (10 mM) abolished contractions to low concentrations (1 ± 3 nM) of U46619, but at 100 nM U46619 there was only partial inhibition (49.3+9.0% vs 125.9+17.7% contraction, P=0.0075). Y27632 (10 mM) signi®cantly shifted the U46619 ). (C) Summary of experiments as shown in (B). Data points are mean+s.e.mean normalized tension (tension (g)/wet weight of the vessel (g)) (n=6 for both groups). Experiments were performed in the presence of 10 mM diltiazem. The smooth curves in this and all other ®gures are ®tted Hill equations.
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Rho-kinase inhibitors and arterial grafts T.J.P. Batchelor et alconcentration-response curve to the right (EC 50 of 18.69+5.39 nM compared to 5.04+0.83 nM in control conditions, P=0.046). Preincubation with 1 mM Y27632 did not signi®cantly inhibit the contractions to 100 nM U46619 (119.3+20.6% vs 125.9+17.7%) ( Figure 4A ). There was, however, a trend towards attenuation of contractions to low U46619 concentrations and, using a more sensitive protocol, a statistically signi®cant dierence was detected ( Figure  4B ,C). Two concentration-response curves were constructed for U46619, the ®rst with U46619 alone and the second (after a washout) with U46619 following a 30-min preincubation with 1 mM Y27632. There was no change in the time-matched control experiments ( Figure 4B ), but in the Y27632 group the contractile responses to low concentrations of U46619 (1 ± 10 nM) were signi®cantly attenuated ( Figure 4C ). A comparison of the pre-and post-incubation protocols ( Figure  5 ) suggests that Y27632 was slightly less potent if applied before rather than after U46619 had evoked contraction.
Y27632 was also a relaxant of contraction evoked by a submaximally eective concentration of endothelin-1 ( Figure  6 ), acting with an EC 50 of 0.53+0.11 mM (n=5).
Discussion
An important ®nding in this study is that contraction of human internal mammary artery induced by low concentrations of thromboxane A 2 occurs independently of Ca 2+ in¯ux. Even contractions induced by high concentrations of agonist are resistant to established blockers of plasma membrane Ca 2+ channels such as diltiazem and SKF96365. Strikingly, however, inhibitors of Rho-kinase abolished contractions. The Rho-kinase inhibitor Y27632 was also shown to be a potent inhibitor of endothelin-induced contraction and resting (agonist-independent) contraction.
The antivasospastic properties of Y27632 and HA1077 are likely to occur as a result of their ability to inhibit Rhokinase. In biochemical assays, Y27632 and HA1077 inhibit Rho-kinase with K i values of 0.14 ± 0.30 mM (Uehata et al., 1997; Ishizaki et al., 2000) and 0.33 ± 0.40 mM (Uehata et al., 1997; Nagumo et al., 2000) . These values are lower than the IC 50 values from our study (0.53/1.67 mM and 3.58 mM for Y27632 and HA1077 respectively) and lower than thè functional' IC 50 values previously reported (Uehata et al., Rho-kinase inhibitors and arterial grafts T.J.P. Batchelor et al1997; Nagumo et al., 2000; Yoshii et al., 1999) . The approximate 10 fold dierence between K i and IC 50 values may arise because of competition between ATP and drug on the Rho-kinase protein (Ishizaki et al., 2000) . At the concentrations used in our study, Y27632 is not thought to have signi®cant inhibitory eects on proteins other than Rhokinase (Uehata et al., 1997; Ishizaki et al., 2000; Nagumo et al., 2000) .
In a porcine model of coronary artery spasm, intravenous administration of either HA1077 (Shimokawa et al., 1999) or Y27632 (Kandabashi et al., 2000) strongly inhibits agonist-induced vasospasm. Indeed, expression of Rhokinase mRNA is signi®cantly increased at the spastic site, suggesting up-regulation of Rho-kinase is in part responsible for coronary artery spasm in ischaemic heart disease. So far, the only in vivo human studies have involved the intraarterial infusion of HA1077 to successfully treat the cerebral vasospasm associated with subarachnoid haemorrhage (Tachibana et al., 1999) . Ours is the ®rst demonstration of the eectiveness of a selective Rho-kinase inhibitor in human artery. It has previously been suggested that Y27632 is less eective when applied before rather than after the vasoconstrictor agonist (Fu et al., 1998; Iizuka et al., 1999) . This eect, of unexplained mechanism, might represent a practical problem in the use of Rho-kinase inhibitors to prevent vasospasm if applied to arteries prior to grafting on to the heart, and thus prior to exposure to endogenous vasoconstrictors. Although a comparison of pre-and post-application of Y27632 did reveal a slightly stronger eect with a postapplication protocol, this was only statistically signi®cant at a high concentration of Y27632. Thus, the discrepancy between pre-and post-application protocols does not appear to be a major factor in human conduit artery.
It has recently been shown that sodium nitroprusside and raised levels of intracellular cyclic GMP (acting through Gkinase) inhibit RhoA in smooth muscle (Sauzeau et al., 2000) . This suggests that nitrovasodilators and phosphodiesterase inhibitors act in part via inhibition of Rho-mediated Ca 2+ -sensitization. It is thus perhaps not surprising that the most eective vasodilators of human LIMA and radial artery previously described act either as nitric oxide donors or by increasing intracellular levels of cyclic GMP (He et al., 1989; Cable et al., 1998; Sadaba et al., 2000; SalmenperaÈ & Levy, 1996; He & Yang, 2000b) .
Intracellular Ca 2+ acts concentration-dependently to regulate contraction. The EC 50 of this concentration-response curve (or the position of the`pCa curve') is modulated as a consequence of Rho-kinase activation, the EC 50 for Ca 2+ becoming smaller (the pCa curve shifting to the left) as a consequence of Ca 2+ -sensitization. Because RhoA appears to be basally active (Fu et al., 1998; Gong et al., 1996) , it follows that the position of the pCa curve is in dynamic equilibrium. Thus, Rho-kinase inhibitors will shift the curve to the right and this presumably explains why Y27632 inhibited resting tone in the human LIMA. It also follows that Rho-kinase inhibitors may be eective against contraction evoked by any endogenous vasoconstrictor in human LIMA. We have shown that Y27632 inhibits contraction evoked by the thromboxane A 2 agonist U46619 (Figures 3 ± 5) , endothelin-1 ( Figure 6 ) and phenylephrine (T Batchelor & D Beech, unpublished observation, 2000) . Even if other agonists were to exert their eects principally via Ca 2+ in¯ux or Ca 2+ release from the stores, inhibition of Rho-kinase should still be eective in inhibiting contraction.
Spasm of arterial grafts used for coronary artery surgery is a factor in determining the survival of both the graft and the patient. Our ®ndings provide the ®rst direct evidence that Rho-kinase inhibitors may be eective in preventing human vasospasm. It remains to be seen whether Rho-kinase inhibitors can be employed clinically. However, we speculate that they may be useful if injected into the mammary bed at the time of surgery, incubated with radial artery grafts prior to implantation, or administered systemically. In the future, methods for inhibiting Ca 2+ -sensitization may include viral transfer of dominant negative constructs of RhoA or Rhokinase. Eective adenoviral gene transfer of nitric oxide synthase has been achieved in human radial arteries with an incubation period of 1 h (Cable et al., 1998) . While our interests lie primarily with the prevention of arterial graft vasospasm, other groups have suggested that Rho-kinase inhibitors may be useful in the treatment of hypertension (Uehata et al., 1997) , coronary artery spasm (Shimokawa et al., 1999; Kandabashi et al., 2000) and cerebral vasospasm following subarachnoid haemorrhage (Tachibana et al., 1999) . Inhibition of Rho-kinase in a rat model also suppresses neointimal proliferation in arteries subjected to injury by balloon angioplasty (Sawada et al., 2000) .
Rho-kinase inhibitors are very eective at preventing agonist-induced vasospasm in human left internal mammary artery, a vessel commonly used as a graft in coronary artery bypass surgery. They prevent spontaneous contraction as well as contraction evoked by several potent endogenous vasoconstrictor substances. The apparent dominance of the Rho-kinase pathway in mediating contraction of human conduit artery suggests this will be an important target for further drug development. The combination of the relaxant and antiproliferative eects of Rho-kinase inhibitors should confer signi®cant therapeutic bene®t.
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